Australia Trial Exposes Employee Doubts About Merck Vioxx Handling
This article was originally published in PharmAsia News
Executive Summary
Australia's Merck, Sharp & Dohme and its U.S. parent, Merck, were the subjects of more doubts cast in a court trial over their innocence of the consequences of their anti-arthritis drug Vioxx (rofecoxib). Plaintiff attorneys showed the jury in a federal court class action trial e-mail traffic that showed some employees expressed concerns about the drug. One was from an employee who said it was "a bit too much to swallow" that Merck was not aware of the drug's risks years earlier than it has admitted and well before it was withdrawn from the market in 2004. Merck has maintained it acted appropriately and responsibly. (Click here for more
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.